The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats

Neuroscience Letters
Shii-Yi YangShih-Jen Tsai

Abstract

Reduced N-methyl-D-aspartate receptor (NMDAR) function may contribute to the pathogenesis of schizophrenia. Sarcosine, a potent glycine transporter inhibitor, can increase synaptic glycine and then promote NMDAR function. We assessed the antipsychotic potential of sarcosine by comparing the abilities of sarcosine and clozapine to restore the prepulse inhibition (PPI) deficit, hyperlocomotion and regional brain c-Fos expression changes caused by an NMDAR antagonist, ketamine. Four groups of rats were given acute injections, including saline+saline, saline+30 mg/kg ketamine, 100mg/kg sarcosine+30 mg/kg ketamine, and 15 mg/kg clozapine+30 mg/kg ketamine. Both sarcosine and clozapine reversed the ketamine-induced PPI deficit and hyperlocomotion. They both did not change ketamine-induced increase in c-Fos expression in the prefrontal cortex and nucleus accumbens. However, in the olfactory bulb, sarcosine, but not clozapine, significantly reduced the ketamine-induced increase in c-Fos expression. Our animal study demonstrated that sarcosine may have antipsychotic potential.

References

Dec 1, 1989·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R S Mansbach, M A Geyer
Aug 1, 1994·The American Journal of Psychiatry·D C JavittJ P Lindenmayer
Jan 1, 1993·Annual Review of Neuroscience·S G Amara, M J Kuhar
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·R BergeronR W Greene
Apr 28, 2000·The American Journal of Psychiatry·B I TuretskyR E Gur
Apr 2, 2003·The American Journal of Psychiatry·Bruce I TuretskyRaquel E Gur
Jul 15, 2003·Current Psychiatry Reports·Paul J Moberg, Bruce I Turetsky
Feb 5, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David FeifelPaul D Shilling
May 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Guochuan TsaiJoseph T Coyle
Dec 14, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Axel Becker, Gisela Grecksch
Jun 15, 2006·Cellular and Molecular Neurobiology·Joseph T Coyle
Jul 31, 2007·Biological Psychiatry·Hsien-Yuan LaneGuochuan E Tsai
Aug 22, 2009·Neuroscience and Biobehavioral Reviews·Viviane Labrie, John C Roder

❮ Previous
Next ❯

Citations

Jul 22, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Philipp SingerBenjamin K Yee
Jan 24, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ching-Ping YangYi-Ming Arthur Chen
Jun 15, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jen-Cheng LinHwei-Hsien Chen
Feb 4, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S A CastnerM Laruelle
Feb 5, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neil DawsonJudith A Pratt
Nov 1, 2013·Nature Reviews. Drug Discovery·Robert J Harvey, Benjamin K Yee
Sep 15, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kazuhiro NakatoShoji Takakura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here